Novo Nordisk A/S
The Dow’s losing streak, fertilizer prices, Novo Nordisk’s new Wegovy shot and more in Morning Squawk
This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Happy Friday. In a tale of two viral hotspots, Polymarket is planning a pop-up bar in Washington, D.C., while a New York City pharmacy is seeing a surge after its feature in FX’s “Love Story.” Stock futures are down this morning after […]
Read More
FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, Feb. 4, 2026. Tom Little | Reuters The Food and Drug Administration on Thursday approved a higher dose version of Novo Nordisk‘s blockbuster weight loss injection Wegovy, as the company pushes to win back market share from […]
Read More
Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial
Eli Lilly on Thursday said its next-generation obesity drug retatrutide cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight. The drug lowered hemoglobin A1c — a key measure of blood sugar levels — by an average of 1.7% to 2% across different doses at […]
Read More
Eli Lilly catches a downgrade as HSBC warns of an overhyped obesity drug market
HSBC analysts just slashed their recommendation on the world’s most valuable pharmaceutical company, Eli Lilly, signaling a potential cooling period for the red-hot obesity drug trade that has come to dominate market narratives of the sector. Analysts led by Rajesh Kumar downgraded Lilly to Reduce from Hold, cutting their target price to $850 from $1,070, […]
Read More
Stocks making the biggest moves premarket: Bumble, Hims & Hers Health, Blue Owl, Netskope & more
Check out the companies making headlines before the bell. Bumble — Bumble shares popped about 21% after the dating app reported strong adjusted EBITDA and revenue results for its fourth quarter. Its first-quarter adjusted EBITDA guidance also beat analyst consensus expectations, per FactSet. Netskope — Shares of the security and networking company plunged 17% on […]
Read More
Stocks making the biggest moves midday: Chevron, Hims and Hers, Xenon Pharma, Vertiv and more
Check out some of the companies making the biggest midday moves: Oil stocks – Oil stocks briefly traded higher as the commodity surged as the Iran War showed no sign of abating. U.S. crude briefly topped $110 per barrel overnight, hitting levels not seen since mid-2022. Chevron earlier hit an all-time high, Talos Energy at […]
Read More
Hims & Hers shares surge 50% after Novo Nordisk drops patent infringement case over compounded weight loss drugs
Novo Nordisk has dropped its legal case against telehealth provider Hims & Hers over patent infringement, after the two companies agreed Hims would sell Novo’s branded medicines through its platform. “We have decided to drop the current court proceedings and, of course, we reserve to bring that back if need be, but I don’t foresee […]
Read More
Stocks making the biggest moves premarket: Hims & Hers Health, oil stocks, Live Nation Entertainment & more
Check out the companies making headlines before the bell. Oil stocks – Oil stocks traded higher as the commodity surged due to the ongoing Iran War. U.S. crude briefly topped $110 per barrel overnight, hitting levels not seen since mid-2022. Talos Energy rose 5%, while Northern Oil and Gas and ConocoPhillips gained 3% and 2%, […]
Read More
Zealand’s stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics’
Wegovy is produced by pharmaceutical company Novo Nordisk and has been approved for specifically for chronic weight management in adults and adolescents. (Photo by Steve Christo – Corbis/Corbis via Getty Images) Steve Christo – Corbis | Corbis News | Getty Images The chief executive of drugmaker Zealand Pharma sought to calm investors about the latest […]
Read More
Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S.
Eli Lilly on Thursday launched a new program designed to help more employers cover obesity drugs in the U.S., targeting a major barrier to access for patients. Lilly and its chief rival, Novo Nordisk, have moved to slash the cash prices of their popular obesity injections for those who want to pay entirely out-of-pocket. But […]
Read More